Most Read News

Revenue for the year increased 20% YoY to ₹4,829 crore, led by increased cargo tonnage and consolidation of acquired units.

Tejas Networks stock has witnessed a total of 38% dip in the last one year, and 11% dip in the last one month.

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

Of the total, ₹1,082 crore worth of projects were secured by the building division. The remaining ₹581 crore worth of orders were bagged by the transport division.

Out of the total April 2025 sales, 24,833 units were sold locally and 2,491 units exported, a balanced input from the domestic and overseas market.

The bank's core operating income, or net interest revenue (NII), rose 8.3% year on year at ₹2,377.4 crore, reflecting sustained business growth

Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.

USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.

Quarterly revenues were 28% higher year on year at ₹4,988.4 crore from ₹3,912.7 crore in Q4 FY24.

Total operating revenue was ₹2,134 crore in the quarter even with last year overall, and showing steady sales in its core verticals